FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention refers to pharmaceutical industry, namely to a combination for intraperitoneal administration, for treatment and/or prevention of recurrent ovarian cancer. Combination for intraperitoneal administration for treating and/or preventing recurrent ovarian cancer in a subject characterized by a malignant tumor or metastases of a malignant tumor, includes DHMEQ or a pharmaceutically acceptable salt thereof and at least one cytostatic or pharmaceutically acceptable salt thereof, cytostatic is cisplatin and/or paclitaxel taken in certain amounts. Pharmaceutical combination for intraperitoneal administration for treating and/or preventing recurrent ovarian cancer in a subject characterized by a malignant tumor or metastases of a malignant tumor, includes a combination and one pharmaceutically acceptable excipient. A method of treating ovarian cancer involves intraperitoneal introduction of a combination.
EFFECT: disclosed combination is effective, non-toxic, stable and has high bioavailability.
9 cl, 4 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING DHMEQ OR ITS ANALOGUES | 2018 |
|
RU2703735C1 |
| USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME | 2021 |
|
RU2821030C1 |
| COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
| APPLICATION OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS IN COMBINED THERAPY FOR OVARIAN CARCINOMA, METHOD OF TREATMENT AND SETS | 2007 |
|
RU2346692C2 |
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| PHARMACEUTICAL COMPOSITION ELICITING ANTITUMOR EFFECT WITH REDUCED ADVERSE EFFECTS AND CONTAINING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2214238C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
| DRUG FOR TREATMENT OF BENIGN AND MALIGNANT TUMOR DISEASE COMPRISING DERIVATIVE OF DYSORAZOL | 2003 |
|
RU2322236C2 |
